Unilife Signs Agreement with Global Pharmaceutical Company Seeking to Use Ocu-Ject

Unilife

today announced the signing of an agreement with a global pharmaceutical company seeking to use the Unilife Ocu-ject™ ocular drug delivery system to deliver a target injectable therapy into the eye. The identity of the global pharmaceutical company, one of the market leaders in ophthalmic therapies, as well as other terms of the agreement are not disclosed for commercial purposes and due to confidentiality requirements. Unilife will begin to generate revenue under the program in January 2014.